EN | TR
E-ISSN: 2547-9431
Evaluation of Response to Therapy in Thyroid Carcinoma Patients after Radioactive Iodine Therapy
PDF
Cite
Share
Request
Review
VOLUME: 1 ISSUE: 1
P: 30-32
December 2016

Evaluation of Response to Therapy in Thyroid Carcinoma Patients after Radioactive Iodine Therapy

Bagcilar Med Bull 2016;1(1):30-32
DOI: 10.5350/BMB2016010108
Lebriz Uslu Besli 1
Ilhami Uslu 2
1. Istanbul Research and Training Hospital, Nuclear Medicine Clinic, Istanbul, Turkey
2. Istanbul University, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Turkey
No information available.
No information available
Received Date: 06.11.2016
Accepted Date: 08.11.2016
PDF
Cite
Share
Request

ABSTRACT

Radioactive iodine therapy is an important treatment modality for differentiated thyroid carcinoma patients. Radioactive iodine, similar to elementary iodine, is concentrated in the thyroid follicular cells after oral application, and it can damage the remnant or malignant thyroid cells. Unlike many antineoplastic drugs, radioactive iodine can easily be applied without causing serious side effects.

Radioactive iodine was first used for the treatment of a differentiated thyroid carcinoma patient in 1949. In Turkey, it has been used in many nuclear medicine centers for treatment of both differentiated thyroid carcinoma and hyperthyroid patients since 1954. For evaluation of response to therapy with radioactive iodine, different clinical, biochemical, scintigraphic, and radiological imaging modalities are available. Today, many international guidelines aid the clinicians in the assessment of therapy response after radioiodine application. This review aims to discuss the methods recommended in current guidelines for therapy response assessment in differentiated thyroid carcinoma patients after radioactive iodine therapy.